Close Menu

NEW YORK (GenomeWeb) – Oppenheimer has initiated coverage of Genomic Health with a rating of Perform, calling the company a leader in diagnostic testing. The investment bank also initiated coverage of Invitae with a rating of Outperform and a $21 12- to 18-month price target, noting that the company will benefit from several growth trends in the genetic testing sector.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.